Compare Novartis AG (NVS) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Zscaler Inc — how do they compare? Novartis AG trades at $143.71 (market cap $268.57B), while Zscaler Inc trades at $231.43 (market cap $35.35B). The key difference: Novartis AG is far larger — about 7.6× Zscaler Inc's market cap, and Novartis AG pays a 3.31% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Zscaler Inc for 41 Days on average.
| NVS | ZS | |
|---|---|---|
Market Cap | $268.57B | $35.35B |
Volume | 1,532,573 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $168.62 | $336.27 |
52-Week Low | $121.80 | $118.05 |
Typical Hold Time | 82 Days | 41 Days |
Enterprise Value | $309.89B | $33.73B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Zscaler (ZS) trades at $230.23, up 7.81% in the last 24 hours, with a bullish technical signal from moving averages. The company reported strong revenue growth, reaching $2.67 billion in 2025, and has beaten EPS estimates for three consecutive quarters. However, it remains unprofitable with a net income margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day on October 6, 2026.
The outlook is mixed: robust revenue growth and AI-driven bookings offer upside, but profitability concerns and high valuation multiples pose risks. Analyst consensus is bullish with a $222.83 price target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
